Bayer publishes findings on gadoquatrane contrast agent for pediatric use
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Study Overview: Bayer released data from the QUANTI Pediatric trial, which tested low-dose gadoquatrane, a gadolinium-based MRI contrast agent for children, using a reduced dose of 0.04 mmol Gd/kg body weight.
Trial Results: The trial successfully met its primary endpoint, showing that the pharmacokinetic behavior of gadoquatrane in children was comparable to that observed in adults.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
